MENU
JUN 20, 2019 12:00 PM PDT

Antiplatelet Agents for Secondary Stroke Prevention - Can We Be More Precise?

Speaker

Abstract

Clopidogrel, an antiplatelet agent frequently used for secondary stroke prevention, is a prodrug that requires both sufficient intestinal absorption and hepatic modification to produce its active metabolite. An individual's ABCB1 alleles affect clopidogrel absorption, while one's CYP2C19 alleles affect activation of this prodrug. Herein, we explore the role of platelet function assays and genotyping of CYP2C19 and ABCB1 in terms of clopidogrel absorption and activation, and its efficacy in platelet inhibition through three patients who experienced recurrent ischemic stroke despite adherence to clopidogrel. 

Learning Objectives: 

1. Describe the role that platelet function phenotype may play in secondary stroke prevention antiplatelet selection in the future.
2. Describe the role that CYP2C19 and/or ABCB1 genotypes may play in secondary stroke prevention antiplatelet selection in the future.


Show Resources
You May Also Like
MAY 17, 2022 9:00 AM PDT
MAY 17, 2022 9:00 AM PDT
Date: May 17, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 8:00pm (CEST) Gene therapeutics have great potential to treat many severe diseases in an unprecedented, targeted manner. The biopharmace...
NOV 30, 2021 10:00 AM PST
C.E. CREDITS
NOV 30, 2021 10:00 AM PST
Date: November 30, 2021 Time: 10:00am (PDT), 1:00pm (EDT) The prevalence of thyroid disease worldwide has served as a catalyst for healthcare providers to study various tools and methods to...
APR 28, 2022 8:00 AM PDT
APR 28, 2022 8:00 AM PDT
Date: April 28, 2022 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CEST) Human pluripotent stem cells (PSCs) and their derivatives hold great potentials in...
DEC 01, 2021 7:00 AM PST
C.E. CREDITS
DEC 01, 2021 7:00 AM PST
Date: December 01, 2021 Time: 7:00am (PST), 10:00am (EST) In the era of immuno-oncology, there is a growing need for the identification of new biomarkers predictive for sensitivity to anti-P...
MAY 24, 2022 11:00 AM PDT
MAY 24, 2022 11:00 AM PDT
Date: May 24, 2022 Time: 11:00am (PDT), 2:00pm (EDT), 7:00pm (CEST) NGS tumor profiling has become the mainstay of modern cancer therapy. Several NCCN-guided and FDA-approved therapies are c...
MAR 30, 2022 6:00 AM PDT
MAR 30, 2022 6:00 AM PDT
Targeted NGS has been instrumental in helping the healthcare community deliver on the promise of precision medicine. The Ion Torrent Genexus Integrated Sequencer has enabled targeted genomic...
JUN 20, 2019 12:00 PM PDT

Antiplatelet Agents for Secondary Stroke Prevention - Can We Be More Precise?



Show Resources
Loading Comments...
Show Resources